stoxline Quote Chart Rank Option Currency Glossary
  
Dr. Reddy's Laboratories Limited (RDY)
74.82  -1.96 (-2.55%)    03-01 16:00
Open: 74.66
High: 75.15
Volume: 165,044
  
Pre. Close: 76.78
Low: 74.2
Market Cap: 12,458(M)
Technical analysis
2024-03-01 4:54:53 PM
Short term     
Mid term     
Targets 6-month :  90.77 1-year :  106.02
Resists First :  77.72 Second :  90.77
Pivot price 75.94
Supports First :  72.47 Second :  69.23
MAs MA(5) :  76.52 MA(20) :  75.2
MA(100) :  69.14 MA(250) :  64.87
MACD MACD :  1.5 Signal :  1.6
%K %D K(14,3) :  67.3 D(3) :  78.5
RSI RSI(14): 53
52-week High :  77.72 Low :  53
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RDY ] has closed above bottom band by 22.1%. Bollinger Bands are 16% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 75.3 - 75.72 75.72 - 76.19
Low: 72.99 - 73.47 73.47 - 73.99
Close: 73.91 - 74.75 74.75 - 75.66
Company Description

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Headline News

Sat, 02 Mar 2024
Dr. Reddy's Laboratories (NYSE:RDY) Shares Gap Down to $76.78 - MarketBeat

Fri, 01 Mar 2024
JNJ: 3 Pharma Stocks With Prescription for Stability and Value in March - StockNews.com

Fri, 01 Mar 2024
Dr. Reddy's Laboratories Limited (NYSE:RDY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Wed, 28 Feb 2024
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term - Yahoo Finance

Wed, 28 Feb 2024
Rhumbline Advisers Boosts Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY) - AmericanBankingNEWS

Sun, 25 Feb 2024
Dr. Reddy's Laboratories Limited (NYSE:RDY) Holdings Boosted by Nordea Investment Management AB - AmericanBankingNEWS

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
Shares Out 23,210 (M)
Shares Float 0 (M)
Held by Insiders 1.6652e+008 (%)
Held by Institutions 1.1982e+008 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 8.098e+010
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.3
Profit Margin 952.3 %
Operating Margin 19.2 %
Return on Assets (ttm) 24.7 %
Return on Equity (ttm) 12.3 %
Qtrly Rev. Growth 2.713e+011 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 3.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 7
Price to Book value 7.26
Price to Sales 8.11862e+010
Price to Cash Flow 1.73657e+012
Stock Dividends
Dividend 767980
Forward Dividend 849480
Dividend Yield 1026440%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android